Syncom Formul.

{
  "main_header": {
    "sid": 831770,
    "name": "Syncom Formul.",
    "stock_name": "Syncom Formul.",
    "full_name": "Syncom Formulations (India) Ltd",
    "name_url": "stocks-analysis/syncom-formul",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "12.12",
    "chg": -0.26,
    "chgp": "-2.1%",
    "dir": -1,
    "prev_price": "12.38",
    "mcapval": "1,145.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524470,
    "symbol": "SYNCOMF",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE312C01025",
    "curr_date": "Mar 13",
    "curr_time": "",
    "bse_nse_vol": "18.32 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 13, 2026",
    "traded_date_str": "2026 03 13",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/syncom-formul-831770-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-3892101",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SyncomFormulati_mojoScore_3892101.png",
        "date": "2026-03-15 10:10:23",
        "description": "Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Why is Syncom Formulations (India) Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-syncom-formulations-india-ltd-fallingrising-3875039",
        "imagepath": "",
        "date": "2026-03-06 01:18:20",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>On 05-Mar, Syncom Formulations closed at ₹11.96, down by ₹0.16 or 1.32% from the previous session. This decline extends a losing streak that has persisted for four consecutive trading days, during which the stock has fallen by 6.85%. This recent performance starkly contrasts with the benchmark Sensex, which declined by only 2.71% over the same one-week period, highlighting Syncom’s relative weakness in the current market environment.</p>\n<p>Over longer time horizons, the stock’s underperformance is even more pronounced. Year-to-date, Syncom Formulations has declined by 16.19%, significantly lagging the Sensex’s 6.11% fall. Over the past year, the stock has dropped 24.16%, while the Sensex has gained 8.53%. These figures underscore ..."
      },
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-3868918",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SyncomFormulati_mojoScore_3868918.png",
        "date": "2026-03-04 10:10:34",
        "description": "Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Syncom Formulations (India) Ltd Falls to 52-Week Low Amid Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syncom-formulations-india-ltd-falls-to-52-week-low-amid-continued-downtrend-3864816",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SyncomFormulati_priceRelatedfactors_3864816.png",
        "date": "2026-03-02 12:27:13",
        "description": "Syncom Formulations (India) Ltd has touched a new 52-week low of Rs.11.36 today, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have underperformed both its sector and the broader market, reflecting persistent challenges in its financial performance and market positioning."
      },
      {
        "title": "Syncom Formulations (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/syncom-formulations-india-ltd-is-rated-sell-3849276",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SyncomFormulati_mojoScore_3849276.png",
        "date": "2026-02-21 10:10:31",
        "description": "Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 February 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Syncom Formulations Shares Shift to Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syncom-formulations-shares-shift-to-bearish-momentum-amid-technical-downgrade-3847747",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SyncomFormulati_technicaldot_3847747.png",
        "date": "2026-02-20 08:03:24",
        "description": "Syncom Formulations (India) Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The pharmaceutical company’s shares have declined by 4.04% recently, reflecting growing investor caution amid deteriorating technical parameters and a downgrade in its Mojo Grade from Hold to Sell."
      },
      {
        "title": "Syncom Formulations (India) Ltd: Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syncom-formulations-india-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3845079",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SyncomFormulati_technicaldot_3845079.png",
        "date": "2026-02-18 08:02:40",
        "description": "Syncom Formulations (India) Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from bearish to mildly bearish trends. Despite a modest daily gain of 1.03%, the stock’s overall technical profile remains cautious, reflecting mixed signals from MACD, RSI, moving averages, and other momentum oscillators. Investors in the Pharmaceuticals & Biotechnology sector should carefully analyse these developments as the stock navigates a challenging market environment."
      },
      {
        "title": "Syncom Formulations Shares Shift to Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syncom-formulations-shares-shift-to-bearish-momentum-amid-technical-downgrade-3843531",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SyncomFormulati_technicaldot_3843531.png",
        "date": "2026-02-17 08:05:00",
        "description": "Syncom Formulations (India) Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish territory. The company’s stock price has declined by 3.28% recently, reflecting growing investor caution amid mixed signals from moving averages, MACD, and other technical parameters."
      },
      {
        "title": "Syncom Formulations Gains 3.47%: 3 Key Factors Driving the Week’s Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syncom-formulations-gains-347-3-key-factors-driving-the-weeks-momentum-3839654",
        "imagepath": "",
        "date": "2026-02-14 14:07:43",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>09 Feb:</strong> Stock surges 5.83% on technical upgrade to Hold</p>\n                    <p><strong>10 Feb:</strong> Technical momentum shifts amid mixed signals, stock gains 0.14%</p>\n                    <p><strong>12 Feb:</strong> Q3 FY26 results show strong profit growth despite revenue concerns</p>\n                    <p><strong>13 Feb:</strong> Stock closes the week at ₹14.02, down 1.54% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.13.55</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div..."
      }
    ],
    "total": 259,
    "sid": "831770",
    "stock_news_url": "https://www.marketsmojo.com/news/syncom-formulations-india-831770"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "13-Feb-2026",
      "details": "Submission of Press Clipping Related to extract of Un-Audited Financial Result for the Quarter and Nine months ended on 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Regulation 33(3) Of SEBI (LODR) Regulations 2015 - Submission Of Standalone & Consolidated Unaudited Financial Results Along With Limited Review Report For The Quarter And Nine Months Ended On 31St December 2025",
      "datetime": "12-Feb-2026",
      "details": "Submission of Unaudited standalone and Consolidated Financials as an outcome of Board meeting held on 12th February 2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Intimation Of Holding 5/2025-26 Board Meeting For Consideration And Approval Of The Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 31St December 2025.",
      "datetime": "04-Feb-2026",
      "details": "Syncom Formulations India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve Pursuant to Regulation 29(1) (a) of SEBI (LODR) Regulations 2015 read with SEBI (PIT) Regulations 2015 as amended from time to time we are pleased to inform that 5/2025-26 Meeting of the Board of Directors of the Company is scheduled to be held on Thursday the 12th day of February 2026 at 3:00 P.M. at the Corporate Office situated at 207 Saket Nagar Near Saket Club Indore (M.P.) 452018",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has declared <strong>3%</strong> dividend, ex-date: 09 Sep 22",
          "dt": "2022-09-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>1:10</strong> stock split, ex-date: 19 Aug 13",
          "dt": "2013-08-19",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>5:2</strong> bonus issue, ex-date: 19 Aug 13",
          "dt": "2013-08-19",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Syncom Formulations (India) Ltd has announced <strong>1:2</strong> rights issue, ex-date: 13 May 09",
          "dt": "2009-05-13",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Syncom Formulations (India) Ltd is Rated Sell

2026-03-15 10:10:23

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Why is Syncom Formulations (India) Ltd falling/rising?

2026-03-06 01:18:20

Recent Price Movement and Market Performance

On 05-Mar, Syncom Formulations closed at ₹11.96, down by ₹0.16 or 1.32% from the previous session. This decline extends a losing streak that has persisted for four consecutive trading days, during which the stock has fallen by 6.85%. This recent performance starkly contrasts with the benchmark Sensex, which declined by only 2.71% over the same one-week period, highlighting Syncom’s relative weakness in the current market environment.

Over longer time horizons, the stock’s underperformance is even more pronounced. Year-to-date, Syncom Formulations has declined by 16.19%, significantly lagging the Sensex’s 6.11% fall. Over the past year, the stock has dropped 24.16%, while the Sensex has gained 8.53%. These figures underscore ...

Read full news article

Syncom Formulations (India) Ltd is Rated Sell

2026-03-04 10:10:34

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Syncom Formulations (India) Ltd Falls to 52-Week Low Amid Continued Downtrend

2026-03-02 12:27:13

Syncom Formulations (India) Ltd has touched a new 52-week low of Rs.11.36 today, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have underperformed both its sector and the broader market, reflecting persistent challenges in its financial performance and market positioning.

Read full news article

Syncom Formulations (India) Ltd is Rated Sell

2026-02-21 10:10:31

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 February 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Read full news article

Syncom Formulations Shares Shift to Bearish Momentum Amid Technical Downgrade

2026-02-20 08:03:24

Syncom Formulations (India) Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The pharmaceutical company’s shares have declined by 4.04% recently, reflecting growing investor caution amid deteriorating technical parameters and a downgrade in its Mojo Grade from Hold to Sell.

Read full news article

Syncom Formulations (India) Ltd: Technical Momentum Shifts Amid Mixed Indicator Signals

2026-02-18 08:02:40

Syncom Formulations (India) Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from bearish to mildly bearish trends. Despite a modest daily gain of 1.03%, the stock’s overall technical profile remains cautious, reflecting mixed signals from MACD, RSI, moving averages, and other momentum oscillators. Investors in the Pharmaceuticals & Biotechnology sector should carefully analyse these developments as the stock navigates a challenging market environment.

Read full news article

Syncom Formulations Shares Shift to Bearish Momentum Amid Technical Downgrade

2026-02-17 08:05:00

Syncom Formulations (India) Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish territory. The company’s stock price has declined by 3.28% recently, reflecting growing investor caution amid mixed signals from moving averages, MACD, and other technical parameters.

Read full news article

Syncom Formulations Gains 3.47%: 3 Key Factors Driving the Week’s Momentum

2026-02-14 14:07:43

Key Events This Week

09 Feb: Stock surges 5.83% on technical upgrade to Hold

10 Feb: Technical momentum shifts amid mixed signals, stock gains 0.14%

12 Feb: Q3 FY26 results show strong profit growth despite revenue concerns

13 Feb: Stock closes the week at ₹14.02, down 1.54% on the day

Week Open

Rs.13.55

Week Close

Read full news article

View All News